Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

170.87 +1.55 (+0.92%)
Delayed Quote Updated: 4:00 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
News headline image
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch ↗
Gilead Sciences (NASDAQ:GILD) is preparing for a potential launch of its multiple myeloma cell therapy anito-cel, with plans to build on the treatment-center relationships and manufacturing... 
Via MarketBeat
News headline image
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? ↗
The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters. 
Via The Motley Fool
Topics Stocks
News headline image
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment ↗
Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment. 
Via Investor's Business Daily
News headline image
Compugen (CGEN) Q3 2026 Earnings Call Transcript ↗
Enrollment in the MAIA-Ovarian trial is complete and data is due by early 2027. 
Via The Motley Fool
Topics Earnings
Gilead Sciences (NASDAQ:GILD): A Dividend Quality Candidate for Income Investors ↗
Via Chartmill
News headline image
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
From Gabelli Funds
Via GlobeNewswire
News headline image
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation ↗
These are among the best the industry has to offer. 
Via The Motley Fool
Topics Intellectual Property
News headline image
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Line ↗
Via Chartmill
News headline image
Vir Bio (VIR) Q3 2026 Earnings Call Transcript ↗
Gilead deal and 2028 cash runway frame upcoming hepatitis data. 
Via The Motley Fool
Topics Earnings
News headline image
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. ↗
Gilead Sciences increased its quarterly dividend by 3.8% this year. 
Via The Motley Fool
News headline image
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call ↗
Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the... 
Via MarketBeat
Topics Earnings
News headline image
3 S&P 500 stocks we think twice about
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Nasdaq 100 stocks to own for decades and 1 we brush off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ... 
Via StockStory
News headline image
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi... 
Via StockStory
News headline image
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp... 
Via StockStory
News headline image
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio... 
Via StockStory
News headline image
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November ↗
The company is having a great year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma... 
Via StockStory
Topics Artificial Intelligence
News headline image
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year... 
Via StockStory
S&P 500 Gap Movers for October 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Gilead (GILD) Q3 2026 Earnings Call Transcript ↗
Base business sales surged 16%, marking strongest growth in over a decade. 
Via The Motley Fool
Topics Earnings
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call ↗
Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove... 
Via MarketBeat
Topics Earnings
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗
Via Chartmill
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.